- Home
- KG vs IBIO Comparison
KG vs IBIO Comparison
Compare KG & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KG | IBIO |
|---|---|---|
| Founded | N/A | 2008 |
| Country | Bermuda | United States |
| Employees | 44 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.3M | 72.2M |
| IPO Year | N/A | 2009 |
Fundamental Metrics
Financial Performance| Metric | KG | IBIO |
|---|---|---|
| Price | $9.53 | $1.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.75 |
| AVG Volume (30 Days) | 10.7K | ★ 837.9K |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 73.08 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.38 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.07 | $0.56 |
| 52 Week High | $35.37 | $3.82 |
Technical Indicators
Market Signals| Indicator | KG | IBIO |
|---|---|---|
| Relative Strength Index (RSI) | 44.02 | 33.78 |
| Support Level | $9.90 | $1.43 |
| Resistance Level | $10.74 | $1.81 |
| Average True Range (ATR) | 0.66 | 0.13 |
| MACD | -0.07 | -0.02 |
| Stochastic Oscillator | 34.81 | 12.97 |
Price Performance
Historical ComparisonAbout KG Kestrel Group Ltd.
Kestrel Group Ltd specializes in providing fronting services to insurance program managers, MGAs, reinsurers, and reinsurance brokers with two reportable segments: Program Services and Legacy Reinsurance. The Group facilitates insurance transactions utilizing its management contracts with four insurance carriers. Its line business includes casualty, workers' compensation, catastrophe-exposed property, and non-catastrophe-exposed property, with diverse risk durations, sizes, and product types.
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.